Six technology appraisals (TAs) have been published by NICE, detailing evidence-based recommendations regarding whether the following drugs should be used for the specified indication:
- TA446—Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
- TA447—Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
- TA448—Etelcalcetide for treating secondary hyperparathyroidism
- TA449—Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
- TA450—Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
- TA451—Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia.
NICE TAs assess the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, as well as procedures, devices, and diagnostic agents. If the TA recommends a treatment as an option, the NHS must make sure it is available within 3 months (unless otherwise specified) of the TA publication date.